It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cellmediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms. Oncogene (2008) 27, 5894-5903; doi:10.1038 /onc.2008 Keywords: tumour immunity; tumour escape; tumour microenvironment; immunosuppression; immunosurveillance
The tumour microenvironment and immune suppression
Compelling data support the view that the immune system is important for the control of neoplastic development and growth Smyth et al., 2006; Bui and Schreiber, 2007) . If innate or adaptive immunity becomes impaired or suppressed, tumour development can occur. In mouse models, it was demonstrated that the loss of immune function, especially affecting interferon-g (IFN-g) production, T lymphocytes and natural killer cells or their effector mechanisms, resulted in a significantly elevated incidence and rate of spontaneous, chemically induced or autochthonous tumour formation (Smyth et al., 2000 (Smyth et al., , 2006 Takeda et al., 2001; Pollard, 2004; Dunn et al., 2006; Bui and Schreiber, 2007; Lin and Pollard, 2007; Street et al., 2007) . Similarly, immunocompromised patients, particularly transplant recipients, appear to be more susceptible to certain types of neoplasms (Penn, 1999; Pawelec et al., 2002) . Thus, the generation and regulation of appropriate pro-inflammatory interactions can indeed control and promote the eradication of susceptible neoplastic populations.
However, tumour cells within the mass or lesion can also employ mechanisms that circumvent or usurp these immune reactions to enhance their own growth. These malignant populations may do so in a number of ways, chiefly through the production of diverse tumour-derived factors (TDFs) that function to (a) facilitate tumour growth in an autocrine fashion, (b) recruit host stromal cells, namely fibroblasts and tumour-associated macrophages, which further nurture the tumorigenic process, (c) recruit and engage multiple host immune suppressive cell populations that downregulate innate or adaptive immune responses locally or systemically and/or (d) suppress innate or adaptive immune responses directly. However, when a productive antitumour immune response does develop, it can also serve as a biological selective pressure that promotes the emergence of more aggressive tumour escape variants in a process termed cancer immunoediting Smyth et al., 2006; Bui and Schreiber, 2007) . Therefore, although the goal of an antitumour response is to mediate tumour cell destruction, this very response may also have unintended tumour-promoting consequences due to immunoediting or the induction of an inflammatory response that may stimulate tumour progression Smyth et al., 2006; Bui and Schreiber, 2007; Stewart et al., 2007) .
In addition to the TDF-mediated mechanisms of tumour escape that drive a highly immune suppressive microenvironment, neoplastic cells may escape the immune response by avoiding or reducing the efficiency of immune recognition. In the case of tumour-associated antigens (TAA), which represent self-Ag and are shared by normal host cells, the efficiency of Ag recognition, however, may not be affected. Instead, the naive peripheral T-cell pool will likely not contain highaffinity T cells that will recognize self-Ag and any lower affinity T cells that will be present, may be tolerized or rendered anergic. TAA-specific, but functionally unresponsive, T-cell populations are evident in tumour-infiltrating lymphocytes obtained from patients with malignant melanoma (Dudley and Rosenberg, 2003) . Following appropriate ex vivo stimulation, however, these tumour-infiltrating lymphocytes can recover functional competence and mediate tumour regression in at least subsets of patients receiving autologous adoptive tumour-infiltrating lymphocyte therapy, particularly under joint conditions of nonmyeloablative chemotherapy (Dudley et al., 2002; Dudley and Rosenberg, 2003) . This clinical scenario indicates that the immune response can play an integral role in the neoplastic process and, if appropriately manipulated, can mediate significant antitumour activity. Moreover, these observations reveal that the tumour microenvironment can adversely affect the competence of tumour-reactive lymphocytes and, in conjunction with depressed pro-inflammatory signals, facilitate tumour escape. Thus, it has become a challenging task to induce productive antitumour immune responses against 'self-TAA' (Pardoll, 2003) .
It has also been demonstrated that clonally expanded tumour cells are genetically unstable and can readily acquire new mutations or downregulate tumour suppressor genes through epigenetic mechanisms (Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 2004) . Indeed, these genetic and epigenetic alterations underlie the mechanisms for aggressive tumorigenic behaviour, including the nature and types of TDF that contribute to tumour immune escape. During the evolution of the tumorigenic process, there is a dynamic cross talk with host cells, which can include those of the immune system. Therefore, productive tumour development may depend, in part, on the balance of positive and negative signals generated during these host-tumour interactions.
The phenomenon of immune tolerance
It is well recognized that neoplastic cells are antigenic, but often weakly to non-immunogenic; that is, they express Ag against which an immune response could be directed, but lack the capacity to create a pro-inflammatory environment necessary to sustain efficient T-cell activation and clonal expansion following Ag recognition. An important mechanism of tolerance induction is insufficient or inappropriate Ag processing and presentation of TAA by antigen-presenting cells (APCs) (Cuenca et al., 2003) . Ordinarily APCs, mainly dendritic cells (DCs), monocytes/macrophages and activated B cells, express or upregulate relevant major histocompatibility complex (MHC) and costimulatory molecules under the appropriate inflammatory conditions. These cells are then capable of inducing immune activation by presenting TAA through either exogenous or endogenous (that is, cross-priming) pathways to CD4 þ or CD8 þ T cells, respectively. DCs are mainly responsible for the initiation or potentiation of an immune response; however, within a highly immunosuppressive tumour microenvironment, DC may fail to induce effector functions in the Agspecific T cells that they interact with (see also section below on contact-independent mechanisms of tumour escape). Therefore, DCs have been shown to play a major role in dictating whether T-cell priming or tolerance occurs (Steinman et al., 2003) . For full T-cell activation, the DC must have the capacity to process and present TAA to both CD4 þ and CD8 þ T cells and simultaneously supply the relevant costimulatory signals. Such signals include cell-surface expression of a family of B7 molecules, as well as the production of pro-inflammatory cytokines, namely interleukin (IL)-12, which enable productive T-cell activation (Pardoll, 2003; Steinman et al., 2003) . However, inefficient T-cell activation may occur because of the absence of inflammatory mediators and an immunosuppressive or tolerogenic host-tumour microenvironment consisting, in part, of immature DC that fail to express the requisite pro-inflammatory and costimulatory characteristics that are needed to induce a favourable antitumour response.
In the Ag-specific CD4 þ T-cell compartment, progressive tumour growth induces various forms of unresponsiveness and coincides with reduced therapeutic efficacy (Lee et al., 1999; Willimsky and Blankenstein, 2005) . Therefore, in vivo interactions between CD4 þ T cells and their Ag-bearing tumours lead to a functionally heterogeneous population of T cells comprising anergic, naive (unactivated) and inhibitory (regulatory T cells, T reg ) phenotypes (Lee et al., 1999; Willimsky and Blankenstein, 2005; Zhou et al., 2006) . CD8 þ T cells can also exhibit tolerogenic characteristics in tumour-bearing hosts. These characteristics can manifest in a number of ways, such as through ignorance (Ochsenbein et al., 1999) or tolerance to TAA (Overwijk et al., 2003) , or through a phenomenon termed split anergy (Otten and Germain, 1991) by which Ag-reactive CD8 þ T cells could be detected in the draining lymph nodes, but were deficient in one or more effector functions. Overall, the balance of signals favouring immune tolerance over immune activation may explain, in part, tumour progression in the presence of tumour-reactive T cells, which may have been ignored, rendered anergic or even deleted due to mechanisms of tolerance.
So, what are some other key factors in the tumour microenvironment that influence the outcome of tumour regression versus tumour escape? As part of the dynamic dialogue within the tumour microenvironment, tumour cells may escape immune recognition or attack through two general paradigms: (a) tumour cell contact-independent mechanisms that involve the secretion of TDFs, which inhibit immune cells either directly or indirectly through engagement of third-party immune suppressive cell sub-populations; and (b) tumour cell contactdependent mechanisms that involve direct interactions between the tumour cell and the immune cell.
Tumour cell contact-independent mechanisms
Tumour-derived factors Numerous TDFs with pro-apoptotic or immune suppressive properties have been characterized (Figure 1 ), most notably, transforming growth factor-b (TGF-b), vascular endothelial factor (VEGF), IL-10 and prostaglandins (that is, PGE 2 ). Although such factors have diverse and multi-functional consequences, they may act on lymphocytes directly (for example, TGF-b, IL-10) or indirectly (for example, VEGF, PGE 2 ) through host APC populations, such as DCs and monocytes/macrophages, to render them non-stimulatory or tolerogenic for adequate induction of host immune responses.
A pivotal mechanism accounting for the production of such tumour-derived immune suppressive factors involves STAT3 activation (Wang et al., 2004; Kortylewski et al., 2005; Yu et al., 2007) (Figure 1 ). Constitutive STAT3 activity in neoplastic populations drives the production of cytokines, such as IL-10 and VEGF, that inhibit pro-inflammatory reactions within the tumour microenvironment. This, in turn, impairs DC maturation and activation, resulting in populations of DC that are unable to support antitumour immunity. Moreover, such TDFs can induce endogenous STAT3 activation in affected DC populations, which alters their expression of costimulatory molecules and pro-inflammatory cytokine characteristics. Aberrant STAT3 signalling may therefore have profound consequences on both innate and adaptive immunity, and strategies that inhibit STAT3 signalling in neoplastic cells or aberrant APC populations may reinstate APC function and the engagement of antitumour activity. This has been demonstrated by using dominant-negative or antisense oligonucleotide approaches, as well as STAT3 antagonists that impede constitutive tumour-or immune system-associated STAT3 activity (Wang et al., 2004; Kortylewski et al., 2005; Yu et al., 2007) . Figure 1 Cell contact-independent mechanisms of tumour escape. Tumour escape through cell contact-independent mechanisms occurs largely through the secretion of diverse tumour-derived factors (TDFs) with multi-functional consequences. Here, a number of major well-characterized TDFs are illustrated to reveal the complexity of interactions and the biological consequences. TDF may act directly on the tumour cell population itself and/or other host cell types to further advance the malignant process. Among the plethora of TDF that can promote tumour escape, suppress innate or adaptive immunity and facilitate tumour progression include vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), reactive oxygen species (ROS), indoleamine-2,3-dioxgenase (IDO), prostaglandins (for example, PGE 2 ) and transforming growth factor (TGF)-b. Moreover, various myeloid or lymphoid populations are also engaged and exploited in creating an immunosuppressive or tolerogenic network that further compromises the effectiveness of innate or adaptive immunity. These include tumour-associated macrophages (TAMs), regulatory T cells (T reg ), natural killer T cells (NKTs), immature dendritic cells (iDCs), IDO-producing plasmacytoid DC (pDC) and myeloid-derived suppressor cells (MDSCs).
Tumour-derived TGF-b has pleiotropic consequences ( Figure 1 ). It can mediate tumour escape and progression by impacting the biological behaviour of neoplastic cells directly and/or indirectly by affecting immune or stromal elements. Among its numerous activities, TGF-b can promote the proliferation of host stromal cells, such as fibroblasts and tumour-associated macrophages (Pollard, 2004) , which, in turn, may secrete diverse angiogenic factors, such as VEGF Reckamp et al., 2006) . Tumour-associated macrophages are recruited to the site of tumour growth through a host of TDF, including colony-stimulating factor-1 (CSF-1) and members of the monocyte chemoattractant protein family (for example, MCP-1/CCL2). TGF-b also induces stromal cells to produce PGE 2 through the upregulation of cyclooxygenase-2 activity (Reckamp et al., 2006) , which favours tumour cell survival, proliferation and apoptotic resistance.
Tumour-or stromal-derived TGF-b abrogates T-cell differentiation, proliferation and effector function, in part, through the loss of IL-12 production and cytotoxic T lymphocyte lytic capability (Thomas and Massague, 2005; Li et al., 2006) . The production of IL-4 and IL-10 by TGF-b-stimulated stromal cells can also tilt the immune response towards an inappropriate type-2 phenotype, which is unable to sustain effective cell-mediated immunity. Increased production of PGE 2 by stromal cells following stimulation by tumour-derived TGF-b will also impair DC function and their ability to appropriately activate an antitumour T-cell response, in part, by decreasing the expression levels of MHC class I and II molecules on these APC (Harizi et al., 2001) . Tumour cells can also promote their own survival through the production of these same TDFs, namely PGE 2 , TGF-b, VEGF, IL-4 and IL-10 (Figure 1 ). Such TDFs, in turn, can upregulate the expression of additional angiogenic activators, such as matrix metalloproteinase-2 and matrix metalloproteinase-9 (Vakkila and Lotze, 2004) , as well as anti-apoptotic genes that encode c-FLIP, Bcl-x L and Mcl-1 (Espana et al., 2004; Jung et al., 2004) . Increased resistance to apoptosis coupled with increased angiogenic activity and invasiveness through VEGF and matrix metalloproteinase production are key acquisitions that favour tumour escape and progression.
Immune suppressive subsets that contribute to tumour escape As a result of these TDF-induced effects, lymphoid or myeloid populations may also develop into potent immune suppressive subsets that contribute to tumour escape (Figure 1) . In both mice and humans, a number of immune suppressive subsets have been identified, including T reg , myeloid-derived suppressor cells (MDSCs) and indoleamine 2,3-dioxygenase (IDO)-producing DC populations. Also, subsets of CD1-restricted natural killer T cells have been identified in mouse tumour models, which downregulate host immunosurveillance through IL-13 production and recruitment of MDSC (Terabe et al., 2000 (Terabe et al., , 2003 . Although each cell type suppresses systemic and/or adaptive immunity in a unique capacity, they may also interface to maximize immune dysfunction (Figure 1) . CD4 þ CD25 þ T cells, which also express the FoxP3, CTLA-4 and GITR markers ('T reg cells'), are best defined by their ability to suppress effector T-cell function in both animal tumour models and patients bearing a variety of tumour types (Sakaguchi, 2004; Curiel, 2007) . T reg cells occur naturally and act to inhibit autoimmune responses (Shevach, 2000) but can also suppress the generation of tumour-specific T-cell responses (Gallimore and Sakaguchi, 2002) , possibly through similar mechanisms. Increased numbers of T reg cells have been found in the peripheral circulation of patients with a range of cancer types (Liyanage et al., 2002; Ichihara et al., 2003; Ormandy et al., 2005) . In studies of ovarian carcinoma, these cells have been shown to accumulate at the tumour site through CCL22-induced migration (Woo et al., 2001; Curiel et al., 2004) . Strategies that deplete T reg cells have also been shown to improve responses to therapy (Ercolini et al., 2005; Litzinger et al., 2007) . T reg cells can suppress effector T cells and thus prevent the development of antitumour immunity, although the mechanisms by which these cells mediate immunosuppression remain elusive.
Tumour growth has also been shown to be accompanied by the expansion of a unique heterogeneous population of inhibitory myeloid cells, termed MDSC (Figure 1 ), which in mice commonly co-express the CD11b and Gr-1 differentiation markers (Kusmartsev and Gabrilovich, 2006; Nagaraj and Gabrilovich, 2007) . Although more extensively studied in animal models, the generation of similar inhibitory myeloid populations has also been observed in various human cancers including carcinoma of the head and neck, non-small cell lung carcinoma, renal carcinoma, melanoma and adenocarcinomas of the colon, breast and pancreas (Almand et al., 2001; Schmielau and Finn, 2001; Zea et al., 2005; Filipazzi et al., 2007; Ochoa et al., 2007) . Many tumour types have been shown to promote the expansion of MDSC in vivo through the secretion of one or more TDFs such as granulocyte macrophage-CSF, VEGF, IL-10, IL-6, CSF-1 and PGE 2 (Serafini et al., 2004; Rodriguez et al., 2005; Kusmartsev and Gabrilovich, 2006; Nagaraj and Gabrilovich, 2007; Ochoa et al., 2007; Sinha et al., 2007) .
A number of animal studies have implicated these CD11b þ Gr-1 þ cells in the suppression of both CD4 þ and CD8 þ T cell-mediated immunity through diverse pathways (Figure 1) . Some of the mechanisms characterized include (a) the secretion of TGF-b, which downregulates CTL induction (Terabe et al., 2003) ; (b) the production of inhibitory enzymes, namely arginase 1, which leads to arginine depletion, and inducible nitric oxide synthase that results in the generation of reactive oxygen species including nitric oxide, which ultimately alter T-cell signalling, activation and eventually their survival (Bronte and Zanovello, 2005; Kusmartsev and Gabrilovich, 2006; Nagaraj and Gabrilovich, 2007; Ochoa et al., 2007) ; and (c) the promotion of tumour angiogenesis through matrix metalloproteinase-9 production, which regulates in part the bioavailability of VEGF (Yang et al., 2004) .
Although these MDSCs are readily apparent in the bone marrow and peripheral lymphoid organs of mice, they are also found to infiltrate tumour tissue, constituting about 5% of the total mass (Yang et al., 2004) . In fact, strategies to deplete or alter the function of MDSC in vivo can improve antitumour responses alone or in combination with other therapies (Terabe et al., 2003; Rodriguez et al., 2005; Suzuki et al., 2005; Fricke et al., 2007) . In human cancer patients, different phenotypic subsets of 'MDSC-like' cells have been identified, including those that express CD11b and CD15 (Zea et al., 2005; Ochoa et al., 2007) or others that lack CD11b, but express CD33 and CD34 (Almand et al., 2001; Fricke et al., 2007) . Furthermore, it remains to be fully understood whether such MDSC-like populations in humans influence tumour progression. Nonetheless, it has been reported that in patients receiving therapies that modulate 'MDSC-like' populations, immune status or function can be elevated (Mirza et al., 2006; Fricke et al., 2007) .
Finally, in addition to MDSC-mediated arginine depletion as a mechanism of immunosuppression, tryptophan depletion in the tumour microenvironment may elicit a similar adverse functional outcome on T-cell immunity (Zamanakou et al., 2007) . This can be achieved through the action of the enzyme IDO that may be expressed by either neoplastic cells or myeloid populations, such as DC or monocytes/macrophages that infiltrate the tumour lesion (Figure 1) . In animal models, IDO overexpression in immunogenic tumours enhances tumour aggressiveness, whereas, inhibitors of IDO augment CTL activity and reduce tumour growth in vivo. Therefore, it appears evident that tumours develop a parasitic relationship with its host to usurp control of both myeloid and lymphoid compartments to further perpetuate neoplastic growth and progression.
Tumour cell contact-dependent mechanisms
Tumour cells may also escape destruction through three general cell contact-dependent scenarios (Figure 2 ): (1) as a consequence of the loss or downregulation of Figure 2 Cell contact-dependent mechanisms of tumour escape. In addition to the arsenal of cell contact-independent mechanisms, tumour cells have acquired the ability to affect expression of a number of cell-surface molecules required for efficient host T celltumour interactions and tumour cell destruction. Here, tumour escape may result from the loss or downregulation of key receptor/ ligand interactions important for cellular adhesion, immune recognition and activation; acquisition of apoptotic resistance due to the alterations in extrinsic or intrinsic death signalling pathways; or aberrant expression of cell-surface ligands that either downregulate T-cell activity, such as PD-L1/B7-H1 or B7-H4, or mediate T-cell death, such as TRAIL or FasL. PD-1, programmed death receptor-1; TRAIL, TNF-related apoptosis-inducing ligand.
How tumours escape mass destruction TJ Stewart and SI Abrams cell-surface molecules critical for adhesion or immune recognition and activation (for example, MHC/Ag expression or its intracellular components); (2) through aberrant expression and engagement of receptor-ligand interactions that adversely affect lymphocyte survival or their effector functions (for example, Fas ligand (FasL), B7-H1, B7-H4); and (3) through acquisition of genetic or epigenetic alterations that increase apoptotic resistance to death receptor-mediated pathways.
Alterations in receptor-ligand interactions
The downregulation of key cell-surface molecules important for efficient effector-target interactions is a common tactic acquired by neoplastic cells to evade immune recognition and destruction (Whiteside, 2006) (Figure 2) . A frequent abnormality observed in many tumour cells involves alterations in the expression of MHC molecules or in the components of the Ag-processing pathways (Ferris et al., 2006; Lopez-Albaitero et al., 2006; Chang and Ferrone, 2007) . Tumour cells can develop mutations that result in the misprocessing or mispresenting of TAA so that an appropriate Ag-presenting complex (MHC-b 2 microglobulin/peptide) does not form, or cannot be recognized, on the tumour cell surface. Downregulation of, or mutations in, the transporter associated with Agprocessing proteins (TAP1 and TAP2) and components of the immunoproteasome (LMP2 and LMP7) prevents the normal processing of TAA. Generally, tumours are not efficient at directly presenting TAA to the immune system for immune activation or immune-mediated destruction.
In addition to altered MHC/Ag expression, tumour cells fail to function as effective APCs because of the lack of expression of costimulatory molecules that are necessary for proficient T-cell activation. These costimulatory molecules include members of the B7 family, which when downregulated lead to T-cell unresponsiveness despite circumstances of MHC-restricted Ag presentation, as previously discussed. In both animal models and patients with advanced cancer, impairment in T-cell signalling and lytic function has also been demonstrated (Koneru et al., 2005; Whiteside, 2006) . In tumour-infiltrating lymphocytes, there is a decrease in CD3z chain expression, as well as the tyrosine kinases p56 lck and p59 fyn , which all play a role in the proximal TCR signalling events that lead to optimal T-cell activation (Koneru et al., 2005) . Although the precise mechanisms causing alterations in T-cell signalling remain to be fully understood, arginine depletion through MDSC may contribute to this immune defect (Serafini et al., 2004; Rodriguez et al., 2005; Kusmartsev and Gabrilovich, 2006; Nagaraj and Gabrilovich, 2007; Ochoa et al., 2007; Sinha et al., 2007) . Therefore, tumour-induced alterations in TCR signalling can impair adaptive immunity (Figure 2) .
Although the upregulation and engagement of CTLA-4 is not necessarily a tumour escape mechanism, tumour cells can exploit this physiological mechanism for their own advantage (Abrams, 2004; Korman et al., 2006) . In contrast to CD28/B7 engagement, which provides a positive signal important for lymphocyte activation and proliferation, CTLA-4/B7 transduces an opposing negative signal, leading to the subsequent downregulation of the T cell-mediated immune response. Therefore, in neoplasia, a therapeutically relevant T-cell response may be disengaged in the face of progressive tumour growth, which may alter the balance from induction of tumour immunity to one that favours tumour escape (Figure 2) . This possibility is supported by several studies that revealed that CTLA-4 blockade alone or in combination with other therapies enhanced tumour rejection efficiency in vivo (Leach et al., 1996; van Elsas et al., 1999; Phan et al., 2003; Demaria et al., 2005) .
Compared with the restricted expression of CTLA-4, programmed death receptor-1 (PD-1) is expressed on a broad range of immune cells, including mature T and B cells, thymocytes and myeloid cells (Blank and Mackensen, 2007) . The interaction of PD-1 with either of its two ligands, PD-L1 (also known as B7-H1) or PD-L2, has been described to negatively regulate the proliferation and cytokine production of T cells (Freeman et al., 2000; Latchman et al., 2001) . The inhibitory effects of PD-1 were initially observed when PD-1-deficient mice developed autoimmune diseases (Nishimura et al., 2001) . PD-L1 is strongly expressed on a variety of tumours (Iwai et al., 2002) and inversely correlates with patient prognosis (Ohigashi et al., 2005; Thompson et al., 2006) . In animal models, PD-L1/B7-H1 blockade has also been shown to enhance therapeutic efficacy (Hirano et al., 2005) .
Another recently described member of the B7 family, termed B7-H4, is inducibly expressed by myeloid and lymphoid populations (Sica et al., 2003; Flies and Chen, 2007) . As with PD-L1 (B7-H1), the engagement of B7-H4 abrogates T-cell immunity. Here, the mechanism of suppression is thought to involve cell cycle arrest and decreased IL-2 production. Interestingly, several studies now demonstrate the expression of B7-H4 in certain cancer types, including ovarian, renal and mammary carcinomas (Krambeck et al., 2006; Kryczek et al., 2006; Sadun et al., 2007) , which implicates its involvement as a negative regulator of adaptive immunity. This notion is supported by the observation that B7-H4 blockade can augment tumour regression in vivo (Kryczek et al., 2006) . Taken collectively, these studies strengthen the roles of PD-L1 (B7-H1)-and B7-H4-dependent pathways in cell contact-dependent mechanisms of tumour evasion (Figure 2) .
It has been demonstrated, at least in some patients, that the number of circulating T cells, particularly CD8 þ T cells, is decreased (Kuss et al., 2004) because of tumour-induced mechanisms of apoptosis (Hoffmann et al., 2002) . In a mechanism analogous to that involved in the maintenance of T-cell tolerance to normal tissue Ag, it has been proposed that under certain circumstances in vivo, Fas-bearing activated T cells undergo programmed cell death due to their engagement with FasL expressed or released by (that is, soluble FasL) certain tumour types. Tumour-derived microvesicles that contain FasL have also been demonstrated in the sera of cancer patients (Andreola et al., 2002) . Therefore, tumours may escape T-cell attack by inducing apoptosis in the effector cell population either at the site of tumour formation or in circulating T cells, by shedding FasL-containing microvesicles (Figure 2 ). Another death receptor ligand, termed tumour necrosis factor-related apoptosis-inducing ligand, has also been found to be expressed on human melanomas (Bron et al., 2004) and has been associated with the apoptosis of tumour-infiltrating lymphocytes (Giovarelli et al., 1999; Bosque et al., 2005) . It is thought that tumour cells have usurped these physiological death pathways as a means of eliminating infiltrating effector cells to maintain a state of 'privilege' within the tumour microenvironment.
Apoptotic resistance
In terms of molecular events occurring within the neoplastic population, apoptotic resistance is now considered an important hallmark of tumour progression (Hanahan and Weinberg, 2000) . The loss of sensitivity to cell death may reflect resistance to intrinsic (mitochondrial) or extrinsic (death receptor) forms of apoptotic induction. In the case of increased resistance to intrinsic cell death, this may occur through the modulation of pro-and anti-apoptotic members of the Bcl-2 family (Figure 2 ). In the case of increased resistance to extrinsic cell death, such as Fas, this may occur through downmodulation of the receptor itself, defects in caspase family members or dysregulation of the signalling pathway due to the overexpression of key anti-apoptotic proteins, such as FLICE inhibitory proteins (FLIP), inhibitors of apoptosis or survivin, which also affect caspase activation. The potential importance of Fas loss of function in tumour escape and tumour progression reflects two important considerations in cancer biology and tumour immunology: (a) Fas downregulation has been noted in the progression of a range of human malignancies (Keane et al., 1996; Krammer et al., 1998; von Reyher et al., 1998; Owen-Schaub et al., 2000; Worth et al., 2002; Liu et al., 2003; Gordon et al., 2005) ; and (b) if Fas-mediated cytotoxicity is an important host defense mechanism during the effector phase of the immune reaction and if it becomes compromised, this could lead to the emergence of Fas-resistant (Fas lo ) tumour escape variants with potentially enhanced malignant capabilities. Fas lo variants have been shown to exhibit enhanced tumour growth and reduced sensitivity to CTL-based immunotherapy, as shown in mouse models of experimental lung metastasis (Liu et al., 2005b (Liu et al., , 2006 . Ultimately, tumour cells that fail to die, through conventional oncological treatments (that is, radiotherapy, chemotherapy) or experimental immunotherapies, have a clear and distinctive survival advantage to persist, accumulate additional genetic or epigenetic modifications and progress to a more malignantly proficient phenotype.
Several studies have examined whether an antitumour CD8 þ CTL response actually 'selects' such neoplastic sub-populations with enhanced resistance to Fasinduced death (Liu et al., 2005b (Liu et al., , 2006 . These studies revealed that antitumour CTL responses in vivo can concurrently mediate tumour regression and tumour progression through the selection and outgrowth of residual Fas lo variants that possess enhanced malignant potential. In fact, such Fas lo variants were not only more aggressive in vivo, but also significantly more refractory to CTL-adoptive immunotherapy (Liu et al., 2005b (Liu et al., , 2006 . In addition, in both mouse and human solid tumour models, it was demonstrated that biological selection against Fas-responsive cells within parental or primary tumour cell lines, using surrogate sources of Fas engagement, generated Fas lo sub-populations with enhanced malignant ability (Liu et al., 2003; Liu and Abrams, 2003a (Liu et al., 2005a) . Immune selection of Fas lo variants may thus be a novel mechanism of immune escape during the effector/target interaction within the local tumour microenvironment.
Subsequently, microarray studies revealed the differential expression of the two genes affecting Fas responsiveness under pro-inflammatory conditions (that is, following IFN-g sensitization): (a) interferon consensus sequence-binding protein, also known as interferon regulatory factor-8 (IRF-8); and (b) caspase-1 of the Fas signalling pathway (Liu and Abrams, 2003b; Yang et al., 2007) . Incidentally, IRF-8 expression was originally discovered as an IFN-g-inducible transcription factor essential for regulating normal myelopoiesis (Holtschke et al., 1996) . In these solid tumour studies (Liu and Abrams, 2003b; Yang et al., 2007) , IRF-8 expression was directly associated with apoptotic sensitivity, but inversely related to malignant phenotype. Using RNA interference strategies, it was then demonstrated that IRF-8 expression in solid tumours was a causal determinant for their response to cytotoxicity, including Fas-mediated apoptosis, g-irradiation and host antitumour immunosurveillance mechanisms . Although IRF-8 was originally identified in the regulation of normal and neoplastic myeloid development, these findings revealed a new functional role for IRF-8 in non-haematopoietic malignancies. Thus, IRF-8 downregulation in solid neoplasms may provide a previously unrecognized molecular determinant for tumour escape, as well as a potential target for therapeutic modulation.
Conclusions
As the control of tumour development, growth or progression involves dynamic and chronic interactions with the host immune system, alterations in the molecular events of both neoplastic tissue and key elements of the immune system will collectively influence malignant proficiency. The mechanisms of tumour escape are broad and complex, and reflect both cell contact-dependent and -independent interactions. It is also likely that new mechanisms of tumour escape will be identified over time, as more knowledge and insights are gained in cancer biology. Nevertheless, the net effect of these interactions is a highly immunosuppressive or hostile environment that favours tumour cell survival and proliferation, and the disengagement or inactivation of critical host defense mechanisms. These tumour escape mechanisms therefore represent potentially significant challenges to successful cancer immunotherapy. It is important to emphasize that because neoplastic progression is a dynamic, chronic and complex process, it is likely that varying and distinct combinations of factors, as opposed to any single factor alone, interface to impact the outcome between tumour immunity and tumour escape. Accordingly, each preclinical or clinical situation needs to be assessed carefully to best understand and predict the potential physiological benefit of immune intervention, and whether the therapeutic regimen has the capacity to overcome such defined mechanisms of tumour self-protection or escape.
